Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
Date:4/24/2012

NANJING, China, April 24, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2012 on Wednesday, May 9, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Wednesday, May 9, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.718.354.1231China Domestic toll:800.819.0121 China Domestic mobile toll:400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q1 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 73500159.Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.866.214.5335United States toll:+1.718.354.1232The passcode for replay participants is 73500159. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:In the United States:Yehong ZhangCindy ZhengPresidentBrunswick GroupSimcere Pharmaceutical GroupTel: 1-212-333-3810Tel: 86-25-8556-6666 ext. 8811In Beijing:In Hong Kong:Yue YuJoseph Lo Chi-LunBrunswick GroupBrunswick GroupTel: 86-10-5960-8Tel: 852-3512-5000   

 

 


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Full Year 2011 Results
2. Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
4. Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
5. Simceres Iremod Receives SFDA New Drug Approval
6. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
8. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
9. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
10. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
11. Simcere Announces Recent Progress of Qiangkes Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2020)... ... ... Returning for a 3rd year, one of the most influential voices in ... on Friday, May 29th, at the Cannabis World Congress & Business Exposition ... York, taking place May 28–30, 2020 at the Jacob K. Javits Convention Center in ...
(Date:2/28/2020)... ... 27, 2020 , ... ProMach , a worldwide leader ... the company’s new Senior Vice President for its Pharma Business Line. Reporting to ... and commercial activity for ProMach’s Pharma product brands including NJM and WLS. , ...
(Date:2/28/2020)... BALTIMORE (PRWEB) , ... February 27, 2020 , ... At ... providers anywhere using their phones, computers or tablets with the VA Video Connect application. ... get the care they need via secure, live video telehealth appointments. The VA Video ...
Breaking Medicine Technology:
(Date:2/28/2020)... ... February 28, 2020 , ... BenefitScape, ... to the state of New Jersey in connection with new legislation called the ... every New Jersey resident must either obtain health insurance, have a valid exemption, ...
(Date:2/26/2020)... ... 2020 , ... Announcement Key Points: , Hera and Demeetra ... which is best known for its commercialization of the piggyBac® transposase , ... truly dimeric and demonstrates high fidelity with no detectable off-targets while maintaining robust ...
(Date:2/26/2020)... ... 26, 2020 , ... Join the live webinar ... PhD, Chief Technology Officer, Fluxion Biosciences as he provides an overview of ideal ... high-sensitivity circulating tumor cell (CTC) enrichment and recovery from blood samples, including samples ...
(Date:2/26/2020)... ... February 26, 2020 , ... ... the launch of its new HealthBus Worklflows solution, which will be showcased at ... deploying of client-specific health data exchange workflows to scenarios in days using a ...
(Date:2/23/2020)... , ... February 22, 2020 , ... ... aside, a study conducted by Queendom.com reveals that some people who ... less happy. , Analyzing data from 9,568 who took the Emotional Intelligence ...
Breaking Medicine News(10 mins):